JNJ vs. SPCX: Johnson & Johnson vs. Space Exploration Stock Comparison

Company Profile

Johnson & Johnson (JNJ) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Space Exploration (SPCX) belongs to Communication Services (Telecommunication Services) — their GICS classifications point to very different parts of the market.

Johnson & Johnson (JNJ) has been public since January 2, 1962, giving it decades of market history across multiple cycles, while Space Exploration (SPCX) listed only on June 12, 2026 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Space Exploration (SPCX) has a highly aggressive beta of 5.69, indicating much higher sensitivity to broad-market moves, while Johnson & Johnson (JNJ) is defensive at 0.21 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Both JNJ and SPCX need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Johnson & Johnson (JNJ) earns 20.02% on shareholders’ equity, ranked against its industry; Space Exploration (SPCX) has no ROE this period.

Space Exploration (SPCX) reports a negative net margin of -8.61%, usually indicating a net loss over the period. Meanwhile Johnson & Johnson (JNJ) reports 16.20%, ranking against industry peers normally.

Both Johnson & Johnson (JNJ) at 25.74% and Space Exploration (SPCX) at 27.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Space Exploration (SPCX) at 33.24% clears its industry range for revenue growth, far stronger top-line momentum than Johnson & Johnson (JNJ) at 6.05%, which is closer to a typical peer reading.

Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while Space Exploration (SPCX) at -25,600.00% falls below its industry range — a large difference in per-share earnings trajectories.

Growth Metrics

Financial Strength

Space Exploration (SPCX) at 3.08 carries current ratio above its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.02 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Space Exploration (SPCX) at 0.22 keeps leverage in the lower industry quartile, while Johnson & Johnson (JNJ) at 0.55 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Space Exploration (SPCX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

Space Exploration (SPCX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

Dividend Metrics

Valuation

Johnson & Johnson (JNJ) at 41.92 is near its industry’s usual P/E ratio, while Space Exploration (SPCX) at 583.78 sits above its peer range — an unusually expensive price for SPCX’s trailing earnings.

Johnson & Johnson (JNJ) at 6.69 prices around its industry’s typical P/S ratio, while Space Exploration (SPCX) at 56.91 clears its benchmark range — SPCX looks notably rich on sales.

Both look rich against book: Johnson & Johnson (JNJ) at 8.16 sits in the upper P/B ratio quartile, and Space Exploration (SPCX) at 10.31 prices even higher, above its industry range.

Valuation Metrics